Anticancer agents, cancer inhibitors, and life-extending agents containing novel compounds with mTORC1 inhibitory activity.
Compounds with mTORC1 inhibitory activity address the limitations of existing mTOR inhibitors by specifically targeting cancer cells and promoting apoptosis, offering both cancer treatment and life extension benefits.
Patent Information
- Application Number
- JP2022552065
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2020-09-25
- Filing Date
- 2021-09-24
- Publication Date
- 2026-04-20
- Estimated Expiration
- 2041-09-24
AI Technical Summary
Current mTOR inhibitors, such as rapamycin, are effective anticancer agents but lack specificity for cancer cells and have immunosuppressive side effects, while smaller compounds with similar mTORC1 inhibitory activity are unknown, and mTORC1 inhibitors are needed for both cancer treatment and life extension.
Development of compounds with specific mTORC1 inhibitory activity, represented by substructures (I), (II), and (III), which can be administered to suppress cancer and extend lifespan by targeting the mTORC1 pathway.
The compounds effectively inhibit cancer cell proliferation, induce apoptosis, and extend lifespan by suppressing mTORC1 activity, showing stronger cytotoxicity and specificity for cancer cells compared to rapamycin, with minimal side effects.